S_ary It has been suggested that tamoxifen may improve the efficacy of medical castration with luteinising hormone-releasing hormone analogues, but very few data have so far been published concerning the clinical and endocrinological activity of this therapeutic modality. In this phase II During the 1980s, a novel endocrine tool was developed after the introduction of luteinising hormone-releasing hormone (LH-RH) analogues, which provided a means for decreasing circulating oestrogen levels without the need for irreversible surgical oophorectomy (Santen et al., 1986) .
Most circulating oestrogens in premenopausal woman are synthesised in the ovary under the stimulatory control of pituitary gonadotrophins, which is why the inhibition of ovarian activity is thought to be a valuable approach in the treatment of mammary carcinoma.
During the 1980s, a novel endocrine tool was developed after the introduction of luteinising hormone-releasing hormone (LH-RH) analogues, which provided a means for decreasing circulating oestrogen levels without the need for irreversible surgical oophorectomy (Santen et al., 1986) .
In patients with premenopausal advanced breast cancer, the clinical efficacy of a number of LH-RH analogues has been reported (Klijn and de Jong, 1982; Harvey et al., 1985) and, although the response rates for surgical and medical forms of castration are similar, the use of these analogues leads to a lower rate of morbidity. Goserelin is a potent LH-RH analogue which can be easily administered by means of the monthly injection of a depot formulation (Matta et al., 1988) .
Experience with tamoxifen therapy in young patients is more limited than that acquired in post-menopausal women, but the response to this agent has been reported to be similar to that of oophorectomy (Buchanan et al., 1986) ; nevertheless, despite its antioestrogenic properties, many patients on long-term tamoxifen therapy continue to have regular ovulation and menstrual cycles (Ribeiro and Swindell, 1988) .
It has been suggested that the association of an LH-RH analogue and tamoxifen capable of inducing a so-called 'complete oestrogen blockade' (Klijn and de Jong, 1984) blocking ovarian steroid production with the analogue and, at the same time, using the antioestrogen to counteract any residual oestrogen action on cancer cells in an attempt to obtain an increase in the rate and/or duration of response.
Given the potential benefits and the very few published data concerning this therapeutic approach, the present phase II trial was undertaken by our group with the aim of acquiring further information on the efficacy and toxicity of combined goserelin and tamoxifen treatment in patients with previously untreated premenopausal advanced breast cancer. An attempt was also made to determine the effects of the therapy on the patients' hormonal environment. In the case of treatment discontinuation, patients were followed every 2 months in order to record their survival time. Toxicity was evaluated at each visit according to WHO (1979) criteria.
Endocrine investigations Blood samples for hormonal analysis were taken at baseline (pretreatment) and 2, 6 and 12 months after starting therapy. The samples were collected at the same time of day for each patient throughout the study (between 9.00 and 11.00 h) and the serum was separated and stored at -20-C until assay. Oestradiol (E2) was measured using a radioimmunoassay kit obtained from Diagnostic Products (Los Angeles, CA, USA), which had a sensitivity of 5.5 pmol I-1 and intra-and interassay coefficients of variation of 7% and 8.9% respectively. Follicle-stimulating hormone (FSH), luteinising hormone (LH) and testosterone (T) levels were determined as previously described (Bajetta et al., 1994a) .
For each hormone, all of the samples from the same patient were analysed in the same assay batch. All endocrine evaluations were performed at the Laboratory of Endocrinology of Milan's Istituto Nazionale Tumori.
Analysis of results
The study was planned according to the Simon's optimal two-stage design (Simon, 1989) , in order to test the hypothesis that the true response probability was less than 40% against the alternative hypothesis of a response probability of more than 60%. With type I and II error probability levels of 5% and 10% respectively, this design implies that the treatment must be rejected if fewer than 11 responses are observed at the end of the first stage (25 patients) or fewer than 32 at the end of the second stage (total of 66 patients). Serum T levels did not appear to be affected by treatment (P=0.10), mean androgen value being 1.14±0.17nmoll' after 12 months compared with 1. 19 ± 0.10 nmol 1 at starting therapy.
Convincing evidence exists that LH-RH analogue goserelin is effective in premenopausal patients with advanced breast cancer (Blamey et al., 1992) , but castration levels of E2 are only reached after 3-4 weeks compared with 2-7 days after surgical oophorectomy (Beksac et al., 1983) . Furthermore, treatment with the analogue makes menstruating patients post-menopausal without interfering with androgen precursor aromatisation in peripheral tissues, a process believed to be the major source of circulating oestrogens in post-menopausal woman (Santen, 1990) .
The role of tamoxifen in the managemt of premenopausal breast cancer does not appear to be as well established (Sunderland and Osborne, 1991) , although the increased oestrogen levels reported in young patients on tamoxifen therapy seem to imply a direct gonadal effect of the drug (Manni and Pearson, 1980) . This ovarian stimulation could theoretically reverse the inhibitory effect of tamoxifen on the growth of breast cancer cells, and thus decrease anti-tumour activity.
In the present study, the combination of goserelin and tamoxifen therapy led to a remission rate of 41%, the median duration of response being 13 months. Although our clinical results in terms of remission rate and response duration are similar to those reported for goserelin alone (response rates ranging from 33% to 45% and median response durations ranging from 8 to 15 months; Dixon et al., 1990; Kaufinann et al., 1991; Blamey et al., 1992; Bajetta et al., 1994b) , it remains an open question whether tamoxifen may offer any advantage for patients treated with medical castration by the analogue. No prospective study aesing the efficacy of the combination has yet been published although, in a retrospective study of 50 patients receiving the combination, an overall response rate of only 18% was reported; a further 30% of patients showed stable disease, but no significant survival difference between these two response groups was observed (Dixon et al., 1991) . Recently, updating the results of a large ongoing randomised trial comparing goserelin with goserelin plus tamoxifen therapy, Jonat et al. (1994) have reported that after a median follow-up of 23 months only the time to first progression was significantly longer in the combination group (7 vs 6 months), and that there was no significant difference in either the response rate or survival.
No endocrine antagonistic interaction between goserelin and tamoxifen was observed in our study, in agreement with previously reported data (Walker et al., 1989) effective in suppressing serum levels of this hormone. It must be emphasised that FSH stimulates premenopausal oestrogen synthesis by increasing the generation of molecules of the aromatase enzyme in ovarian granulosa cells (Santen, 1990) .
In conclusion, in this prospective trial, the association of goserelin and tamoxifen proved to be a feasible treatment: it was effective in terms of the endocrine changes induced in the host and was not associated with any increased toxicity. Although our clinical data show that the concurrent use of goserelin and tamoxifen does not appear to provide better results than the analogue alone in the palliation of advanced breast cancer in premenopausal patients, it is necessary to await publication of the definitive results of large wellcontrolled randomised studies before it can be reliably concluded that goserelin and goserelin plus tamoxifen are equivalent therapies, or whether the association may lead to an improvement in survival, which is a more important indicator of true patient benefit. This latter aspect would also be more relevant in view of the renewed interest in ovarian ablation as adjuvant treatment in primary breast cancer, although a higher risk of endometrial cancer has also been reported in tamoxifen users (van Leeuwen et al., 1994) .
